Luminescent Iridium Complex-Peptide Hybrids (IPHs) for Therapeutics of Cancer: Design and Synthesis of IPHs for Detection of Cancer Cells and Induction of Their Necrosis-Type Cell Death

Figure 11

Luminescence microscopic images of (Biorevo, BZ-9000, Keyence) of Jurkat cells stained with 5 and anti-DR5 antibody obtained by protocol presented in Figure 10. (aa–ae) Jurkat cells incubated with anti-DR5 antibody (15 µg/mL) at 4°C for 15 min. (ba–be) Jurkat cells incubated with anti-DR5 antibody (15 µg/mL) at 4°C for 15 min and then with 5 (5 µM) at 37°C for 1 h. (ca–ce) Jurkat cells incubated with 5 (5 µM) at 37°C for 1 h and then with anti-DR5 antibody (15 µg/mL) at 4°C for 15 min. (da–de) Jurkat cells incubated with 5 (10 µM) at 37°C for 1 h and then with anti-DR5 antibody (15 µg/mL) at 4°C for 15 min. (ea–ee) Jurkat cells incubated with 5 (10 µM) at 37°C for 1 h and then in fresh medium for 1 h (2 h in total) and then with anti-DR5 antibody (15 µg/mL) at 4°C for 15 min. (fa–fe) Jurkat cells incubated with 5 (10 µM) at 37°C for 1 h and then in fresh medium for 6 h (7 h in total) and then with anti-DR5 antibody (15 µg/mL) at 4°C for 15 min. Scale bar (white) = 10 µm.